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The impact of anti-HLA antibodies, except for donor-speciﬁc anti-HLA-A, -B, -DRB1 antibodies, on engraft-
ment was retrospectively evaluated in 175 single cord blood transplantations (CBT). Patients and donors had
been typed at HLA-A, -B, and -DRB1 antigens, and anti-HLA antibodies had been screened before trans-
plantation to avoid the use of cord blood (CB) units with corresponding antigens. The median age was 59
(range, 17 to 74) years. Overall, 61% were male, 89% had high-risk disease status, 77% received myeloablative
conditioning regimens, and over 80% were heavily transfused patients. Sixty-nine of the 175 (39.4%) were
positive for anti-HLA antibodies. Thirty-nine patients had antibodies only against HLA-A, -B, or -DRB1, 13 had
antibodies only against HLA-C, -DP, -DQ, or -DRB3/4/5, and 17 had antibodies both against HLA-C, -DP, -DQ, or
-DRB3/4/5 and against HLA-A, -B, or -DRB1. Because CB units had not been typed at HLA-C, -DP, -DQ, or
-DRB3/4/5, it was possible that antibodies against them were unrecognized donor-speciﬁc antibodies. Pa-
tients with antibodies only against HLA-A, -B, or -DRB1 showed comparable neutrophil engraftment rates to
those without antibodies (89.7% versus 83%, P ¼ .65), whereas patients having antibodies against C, DP, DQ, or
-DRB3/4/5 showed lower engraftment rate (66.7%, P ¼ .12), which became statistically signiﬁcant in a sub-
group of HLA-mismatched donor-recipient pairs (50%, P ¼ .01). Our results demonstrated that the presence of
donor nonspeciﬁc anti-HLA-A, -B, -DRB1 antibodies had no signiﬁcant inﬂuence on engraftment, whereas
anti-HLA-C, -DP, -DQ, or -DRB3/4/5 antibodies adversely affect engraftment, possibly because of unrecognized
donor-speciﬁc anti-HLA antibodies against them, especially in HLA-mismatched CBT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Cord blood transplantation (CBT) has become a valuable
alternative for patients who require allogeneic stem cell
transplantation (Allo-SCT) but who lack HLA-identical sib-
ling or a matched unrelated donor [1]. Although the out-
comes of CBT are almost comparable to those of Allo-SCT
using unrelated donor, graft failure (GF), or engraftment
delay, is one of the major concerns after CBT, leading toedgments on page 1639.
quests: Naoyuki Uchida, MD, 2-2-2 Tor-
70, Japan.
omon.gr.jp (N. Uchida).
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14.06.024increased early nonrelapse mortality (NRM) [2-6]. The
pathogenesis of GF is likely multifactorial, and to date,
several factors, including cell dose infused, HLA disparities,
the type of conditioning regimens, and chemo-naïve status
of recipient, have been identiﬁed as risk factors associated
with GF after CBT [1,7-10].
Recently, the impactof anti-HLAantibodies on engraftment
in Allo-SCT has drawn increasing attention because of an
increasing number of patients who undergo Allo-SCT using
HLA-mismatched donors [11]. Recent clinical data demon-
strated that thepresenceof donor-speciﬁc anti-HLAantibodies
(DSA) in the recipient is signiﬁcantly associated with GF in
unrelated Allo-SCT and related haploidentical stem cell trans-
plantation (Haplo-SCT) [11], as well as in CBT. In the setting ofTransplantation.
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because the majority of the patients receive HLA-mismatched
units with a relatively lower cell dose compared with that of
unrelated allo-SCTor haploidentical-SCT recipients. Takanashi
et al. clearly demonstrated that only 32% of patients with DSA
achieve engraftment, compared with 83% of patients without
DSA, in their retrospective analysis of 386 patients who un-
derwent myeloablative single-unit CBT [12]. The negative
impactofDSAonengraftment inCBTwasalso conﬁrmed in the
setting of reduced-intensity conditioning (RIC) and/or double
CBT [13,14], although another study showed no signiﬁcant ef-
fect of DSA on engraftment, probably because of the different
thresholds for thedeﬁnitionofDSApositivity [15]. Basedonthe
growing body of evidence, there has been a consensus thatwe
shouldavoid selecting cordblood (CB)unitswhentheanti-HLA
antibodies are directed against the mismatched HLA of the CB
unit. However, all studies performed in the CBT ﬁeld have
speciﬁcally focusedon anti-HLA-A, -B, and -DRB1antibodies in
the recipient. So far, the impact of anti-HLA antibodies against
HLA-C, -DP -DQ, or DRB3/4/5 has not entirely been evaluated.
Further, clinical signiﬁcance of anti-HLA antibodies not corre-
sponding to HLA antigens expressed on CB remains to be
determined. In this study, we retrospectively evaluated the
impactof a presence of these anti-HLAantibodies onoutcomes
inCBT,with a special focus on its associationwith engraftment.
PATIENTS AND METHODS
Patients and Cord Blood Transplantation
This study included 175 consecutive adult patients who underwent CBT
as their ﬁrst Allo-SCT at Toranomon Hospital from March 2008 through July
2011. All patients received a single CB unit after either myeloablative or RIC
regimens. Conditioning regimens were classiﬁed based on the report by the
Center for International Blood and Marrow Transplant Research [16]. Graft-
versus-host disease (GVHD) prophylaxis consisted of tacrolimus (TAC) plus
mycophenolatemofetil (MMF) or TAC alone. Granulocyte colony-stimulating
factor was administered intravenously from around day 3 until neutrophil
recovery. For disease status, those with hematologic malignancies in ﬁrst or
second complete remission at the time of transplantation, those in the
chronic phase or accelerated phase of chronic myeloid leukemia, and those
with refractoryanemiaofmyelodysplastic syndromeweredeﬁnedasbeing at
standard risk,whereas those in other situationswere deﬁned as being at high
risk. Details of supportive care during transplantation was performed as
previously reported [17,18]. All patients gave written informed consent, and
this study was approved by the institutional review board.
Cord Blood Units and Anti-HLA Antibodies
CB units were obtained from the Japanese Cord Blood Bank Network. In
the JapaneseCordBloodBankNetwork, CBunitswere serologically typedonly
at HLA-A, -B, and -DRB1 locus before selection. The CB unit was selected from
those with no more than 2 antigen-mismatches to recipients and principally
contained 2107 andmore total nucleated cells (TNC) counts per kilogramof
recipientbodyweight. SinceMarch2008,weprospectively screenedanti-HLA
antibodies in recipients before CBT to select proper units of CB without cor-
responding HLA-A, -B, and -DRB1 antigens to DSA. In this study, CB unit with
DSAs against HLA-A, -B or -DRB1 were not selected for transplantation. Anti-
HLA antibodies were tested using LAB Screen PRA and Single Antigen (One
Lambda, Canoga Park, CA) for class I (HLA-A/-B/-C) and class II (HLA-DR/-DP/-
DQ) anti-HLA antibodies [19,20]. Median ﬂuorescence intensity (MFI) of 
1000was deﬁned to be positive. In this analysis, patients positive for anti-HLA
antibodies were divided into 2 groups: group A included patients with anti-
bodies only against HLA-A, -B, or -DRB1 without those against HLA-C, -DP,
-DQ, or -DRB3/4/5, whereas group B included patients having antibodies
againstHLA-C, -DP, -DQ, orDRB3/4/5with orwithout those againstHLA-A, -B,
or-DRB1. BecauseCBunits hadnot been typed atHLA-C, -DP, -DQ, or-DRB3/4/
5, it was possible that patients in group B harbored DSA against them.
Deﬁnitions and Statistical Analysis
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days
with absolute neutrophil count of at least 500 cells/mm3 by 60 days after
transplantation. Platelet engraftmentwas deﬁned as the ﬁrst day of a platelet
count of 20,000/mm3 without transfusion support by 100 days after trans-
plantation. Chimerismwas assessed using ﬂuorescence in situ hybridization
in sex-mismatched donor-recipient pairs, and in sex-matched pairs, PCR fora variable number of tandem repeats was used with donor cells detected at a
sensitivity of 10%. Whole blood, CD3þ cells, or bone marrow cells were
assessed at the time of neutrophil engraftment and repeated as indicated,
according to the patients’ condition. Acute and chronic GVHD were diag-
nosed and graded according to the standard criteria [21,22]. A pre-
transplantation hematopoietic cell transplantation-speciﬁc comorbidity
index score was calculated retrospectively for each patient using previously
reported scoring system [23]. For statistical analysis, categorical variables
were compared by the chi-square test or Fisher exact test, whereas
continuous variables were compared by Wilcoxon rank-sum test. The
probability of overall survival (OS) were estimated using the Kaplan-Meier
method and the groups were compared using the log-rank test. The prob-
abilities of neutrophil and platelet engraftment, relapse, and NRM were
estimated based on cumulative incidence curves [24]. Competing events
were death or relapse without engraftment for neutrophil and platelet
engraftment, death without relapse for relapse, and relapse for NRM. The
groups were compared using Gray’s test. The Cox proportional hazardmodel
and the Fine-Gray proportional hazards model were used to determine the
signiﬁcance of multiple variables in determining these outcomes.
RESULTS
Patient Characteristics
The patients’ characteristics are summarized in Table 1.
Their median age was 59 (range, 17 to 74). One hundred and
seven (61.1%)weremale and156 (89.1%) hadhigh-risk disease
status. Themajorityof thepatients hadextensivepriorhistory
of transfusion, both in red blood cell and platelet concentrate.
One hundred thirty-ﬁve patients (77.1%) were conditioned
with myeloablative regimens, whereas 40 patients received
RIC regimens. One hundred forty-four (82.2%) received TAC
plusMMF for GVHD prophylaxis. Themedian TNC and CD34þ
cells infused were 2.55 (range, 1.67 to 5.65)  107/kg and .91
(.27 to 2.97)  105/kg, respectively. HLA mismatch at HLA-A,
-B, and -DRB1 in host-versus-graft (HVG) direction was 0/6
(n ¼ 4), 1/6 (n ¼ 48), and 2/6 (n ¼ 123).
Anti-HLA Antibodies
Sixty-nine of the 175 (39.4%) patients were positive for
anti-HLA antibodies. The median number of anti-HLA spec-
iﬁcities was 2 (range, 1 to 73), and the median value of
maximum MFI was 2150 (range, 1004 to 16,402). Among the
antibody-positive group, 39 patients had antibodies only
against HLA-A or -B, or -DRB1 (categorized as group A), 13
had antibodies only against HLA-C or -DP, or -DQ, or -DRB3/4/
5, and 17 had antibodies both against HLA-C, -DP, -DQ, or
-DRB3/4/5 and against HLA-A, -B, or -DRB1 (the latter 2 were
categorized as group B). Among the 30 patients who were
categorized as group B, 17 had antibodies against HLA-C,
5 against HLA-DP, 12 against HLA-DQ, and 6 against HLA-
DRB3/4/5, including overlapping cases. Characteristics of
patients with or without anti-HLA antibodies are summa-
rized in Table 1. The antibody-positive group included older
patients than the negative group (P ¼ .01). Patients in the
positive group received a higher TNC dose than the antibody-
negative group (P ¼ .04). The degree of HLA-mismatch in the
HVG direction in the antibody-positive group was sugges-
tively lower than those in antibody-negative group, although
it was not statistically signiﬁcant (P ¼ .06). More intensive
GVHD prophylaxis using TAC plus MMF and RIC regimes
were used in the antibody-positive group, although it was
not statistically signiﬁcant (P ¼ .06 in both).
Effect of Anti-HLA Antibodies on Hematopoietic Recovery
Among the 175 patients, 143 achieved neutrophil
engraftment. In the 32 who did not achieve engraftment, 8
had graft failure and proceeded to second transplantation, 5
had early disease progression, and 19 had NRM. The cumu-
lative incidences of neutrophil and platelet engraftment
Table 1
Characteristics of All Patients and Those with or without Anti-HLA Antibodies
Characteristic All Ab Positive Ab Negative P Value
No. of patients n ¼ 175 n ¼ 69 n ¼ 106
Age, median (range), yr 59 (17-74) 60 (21-73) 57.5 (17-74) .01
Gender
Male 107 (61.1%) 39 (56.5%) 68 (64.1%) .34
Female 68 (38.8%) 30 (43.4%) 38 (35.8%)
Diagnosis
AML 51 (29.1%) 18 (26%) 33 (31.1%) .19
MDS/MPN overt AML 62 (35.4%) 32 (46.3%) 30 (28.3%)
MDS 10 (5.7%) 3 (4.3%) 7 (6.6%)
CML 7 (4%) 1 (1.4%) 6 (5.6%)
ALL 11 (6.2%) 5 (7.2%) 6 (5.6%)
ML 20 (11.4%) 4 (5.7%) 16 (15%)
ATLL 8 (4.5%) 4 (5.7%) 4 (3.7%)
SAA 5 (2.8%) 2 (2.8%) 3 (2.8%)
MM 1 (.5%) 1 (.9%) -
Disease status*
Standard risk 19 (10.8%) 8 (11.5%) 11 (10.3%) .80
High risk 156 (89.1%) 61 (88.4%) 95 (89.6%)
Prior history of RBC transfusion
20 times 149 (85.1%) 55 (79.7%) 94 (88.6%) .11
< 20 times 16 (9.1%) 7 (10.1%) 9 (8.4%)
Unknown 10 (5.7%) 7 (10.1%) 3 (2.8%)
Prior history of PC transfusion
 20 times 155 (88.5%) 58 (84%) 97 (91.5%) .23
< 20 times 14 (8%) 7 (10.1%) 7 (6.6%)
Unknown 6 (3.4%) 4 (5.7%) 2 (1.8%)
HCT-CI score
0 33 (18.8%) 11 (15.9%) 22 (20.7%) .41
1 25 (14.2%) 10 (14.1%) 15 (14.1%)
2 38 (21.7%) 20 (28.9%) 18 (16.9%)
3 37 (21.1%) 12 (17.3%) 25 (23.5%)
 4 42 (24%) 16 (23.1%) 26 (24.5%)
Conditioning regimen
RIC 40 (22.8%) 21 (30.4%) 19 (17.9%) .06
Myeloablative 135 (77.1%) 48 (69.5%) 87 (82.0%)
GVHD prophylaxis
TAC 28 (16%) 6 (8.6%) 22 (20.7%) .06
TAC þ MMF 144 (82.2%) 62 (89.8%) 82 (77.3%)
TAC þ sMTX 3 (1.7%) 1 (1.4%) 2 (1.8%)
Number of TNC infused
Median (range),  107/kg 2.55 (1.67-5.65) 2.70 (1.83-5.09) 2.49 (1.67-5.65) .04
Number of CD34þ cells infused
Median (range),  105/kg .91 (.27-2.97) .91 (.32-2.97) .91 (.27-2.35) .41
HLA antigen mismatch
HVG direction
0 4 (2.2%) 2 (2.8%) 2 (1.8%) .06
1 48 (27.4%) 25 (36.2%) 23 (21.6%)
2 123 (70.2%) 42 (60.8%) 81 (76.4%)
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasms; CML, chronic myelogenous leukemia; ALL, acute
lymphoblastic leukemia; ML, malignant lymphoma; ATLL, adult T cell leukemia/lymphoma; SAA, severe aplastic anemia; MM, multiple myeloma; PC, platelet
concentrate; HCT-CI, Hematopoietic Cell TransplantationeSpeciﬁc Comorbidity Index; RIC, reduced-intensity conditioning; TAC, tacrolimus; MMF, mycophe-
nolate mofetil; sMTX, short-term methotrexate; TNC, total nucleated cells; HVG, host-versus-graft.
Data presented are n (%), unless otherwise indicated.
* Acute leukemia in ﬁrst or second complete remission, CML in chronic phase, MDS in refractory anemia, and severe aplastic anemia were deﬁned as standard
risk. All the others were considered high risk.
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53.5% (95% CI, 45.7% to 60.6%), respectively. The median time
to neutrophil and platelet engraftment were 19 days (range,
11 to 60) and 43 days (range, 24 to 94) after transplantation,
respectively. The presence of anti-HLA antibodies itself had
no signiﬁcant effect on neutrophil and platelet engraftment
(positive versus negative: 79.7% versus 83.0%. P ¼ .44, in
neutrophil [Figure 1A]; 50.7% versus 55.2%, P ¼ .53, in
platelet). The number (5 versus < 5) and intensity
(MFI  2000 versus < 2000) of anti-HLA antibodies also had
no signiﬁcant effect on engraftment. Patients with a higher
degree of HLA-antigen mismatch in the HVG direction (2
versus 0 to 1 antigen mismatch) showed an inferior
neutrophil engraftment rate (79.7% versus 86.5%, P ¼ .02),whereas TNC (2.5  107/kg versus < 2.5  107/kg) did not
affect engraftment in our CBT setting (78.3% versus 85.5%,
P ¼ .62). In multivariate analysis, a higher degree of HLA
mismatch in the HVG direction was the only negative factor
for neutrophil engraftment (hazard ratio [HR], .82; 95% CI,
.68 to .9; P ¼ .03), and presence of anti-HLA antibodies did
not show a statistical signiﬁcance. Regarding the impact of
anti-HLA antibodies other than against HLA-A, -B, -DRB1 on
neutrophil engraftment, group B tended to show lower
engraftment rates (66.7%, n ¼ 30) compared with group A
(89.7%, n ¼ 39) or the negative group (83%, n ¼ 106),
although the difference did not reach statistical signiﬁcance
(Figure 1B) (P¼ .12). In fact, among the 30 patients whowere
categorized as group B, only 20 patients (66%) achieved
Figure 1. Cumulative incidence of neutrophil engraftment in all the studied patients (n¼ 175). (A) The incidence was 79.7% (95% conﬁdence interval [CI], 67.2% to 87.9%)
for the antibodies-positive group (n ¼ 69) and 83.0% (95% CI, 73.8% to 89.2%) for the antibodies-negative group (n ¼ 106), respectively (P ¼ .44). Positive group rep-
resented by dashed line and the negative group represented by solid line. (B) The incidence according to the type of anti-HLA antibodies. Group B tended to show lower
engraftment rates (66.7% [95% CI, 43.8% to 81.9%], n ¼ 30) compared with group A (89.7% [95% CI, 70.6% to 96.7%], n ¼ 39) or the antibodies-negative group (83.0% [95%
CI, 73.8% to 89.2%], n ¼ 106). (P ¼ .12; group B versus negative group). Group A is represented by dotted line, group B by dashed line, and negative group by solid line.
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against HLA-C, -DP, -DQ, or DRB3/4/5, only 8 (61.5%) patients
achieved engraftment.
Among 8 patients who had engraftment failure, 5 had
anti-HLA antibodies (4 in group B and 1 in group A). In the
chimerism analysis, 2 of the 3 patients without antibodies
showed transient donor-dominant chimerism, whereas
recipient cell dominance was observed consistently in all 5
patients with anti-HLA antibodies.
In the subgroup analysis in patients who received 2
antigen-mismatched CB in the HVG direction (n ¼ 123),
overall, the HLA-antibodiesepositive group tended to show
lower engraftment rates compared with the negative group
(Figure 2A) (positive group [n ¼ 81]: 71.4%, negative group
[n ¼ 42]: 84%, P ¼ .07). In this analysis, group A showed
comparable engraftment rates to the negative group,
whereas group B showed extremely low engraftment rates
with statistical signiﬁcance (Figure 2B) (group A [n ¼ 24]:
87.5%, negative group [n ¼ 81]: 84%, group B [n ¼ 18]: 50%.
Group B versus negative group, P¼ .01). Multivariate analysis
in this subgroup showed that group B and patients older thanFigure 2. Cumulative incidence of neutrophil engraftment in patients who received 2 a
83.5%) for the antibodies-positive group (n ¼ 42) and 84.0% (95% CI, 73.1% to 90.7%) fo
represented by dashed line and the negative group represented by solid line. (B) The
engraftment rates (50% [95% CI, 21.6% to 73.1%], n ¼ 18) compared with group A (87.5%
CI, 73.1% to 90.7%], n ¼ 81) with statistical signiﬁcance (P ¼ .01; group B versus negat
negative group by solid line.55 years were identiﬁed as the negative factor for neutrophil
engraftment (HR, 2.79; 95% CI, 1.39 to 5.62; P  .01 in group
B; HR, .66; 95% CI, .44 to .97; P ¼ .03 in elderly patients).
Effect of Anti-HLA Antibodies on Survival
At a median follow up of 18 (range, 5.1 to 46) months, the
cumulative incidence of NRM at 2 years was 34.0% (95% CI,
26.8% to 41.2%). The cumulative incidence of NRM at 2 years
was almost comparable between the anti-HLA antibody-
positive and -negative groups (Figure 3A) (positive group
[n ¼ 69]: 38.3%, negative group [n ¼ 106]: 31.2%; P ¼ .28),
whereas group B tended to show a higher incidence of NRM
compared with the negative group (Figure 3B) (group B
[n¼ 30]: 47.9%; P¼ .07). NRM in group Awas almost identical
to that in the antibodies-negative group (Figure 3B) (group A
[n ¼ 39]: 31.5%). Early NRM within 28 days after trans-
plantationwas signiﬁcantly higher in group B comparedwith
other groups (20% in group B, 7.7% in group A, 6.6% in
negative group; group B versus negative, P ¼ .03). Two-year
OS for the entire study population was 45.1% (95% CI, 37.1%
to 52.7%). The OS at 2 years was almost comparable betweenntigen-mismatched CB (n ¼ 123). (A) The incidence was 71.4% (95% CI, 53.5% to
r the antibodies-negative group (n ¼ 81), respectively (P ¼ .07). Positive group
incidence according to the type of anti-HLA antibodies. Group B showed lower
[95% CI, 57.3% to 96.9%], n ¼ 24) or the antibodies-negative group (84.0% [95%
ive group). Group A is represented by dotted line, group B by dashed line, and
Figure 3. Cumulative incidence of nonrelapse mortality (NRM) (n ¼ 175). (A)
NRM at 2 years was 38.3% (95% CI, 26.4% to 50.0%) for the antibodies-positive
group (n ¼ 69) and 31.2% (95% CI, 22.4% to 40.3%) for the antibodies-negative
group (n ¼ 106), respectively (P ¼ .28). Positive group represented by dashed
line and the negative group represented by solid line. (B) NRM according to the
type of anti-HLA antibodies. Group B showed a signiﬁcantly higher incidence
of NRM (47.9% [95% CI, 27.4% to 65.9%], n ¼ 30) compared with group A (31.5%
[95% CI, 17.5% to 46.5%], n ¼ 39) or the antibodies-negative group (31.2% [95%
CI, 22.4% to 40.3%], n ¼ 106). (P ¼ .07; group B versus negative group). Group A
is represented by dotted line, group B by dashed line, and negative group by
solid line.
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(positive group [n ¼ 69]: 42.9%, negative group [n ¼ 106]:
46.2%; P ¼ .47), although group B had a tendency of
decreased OS rate compared with the negative group
(Figure 4B) (group B [n ¼ 30]: 35.1%; P ¼ .26).
DISCUSSION
The aim of this study was to evaluate the effect of anti-
HLA antibodies, except for donor-speciﬁc anti-HLA-A, -B,
-DRB1 antibodies, on engraftment after single CBT. In this
study, we demonstrated that the presence of non-DSA had
no signiﬁcant inﬂuence on engraftment, NRM, and OS afterFigure 4. Probability of overall survival (OS) (n ¼ 175). (A) OS at 2 years was 42.9% (95
CI, 35.5% to 56.3%) for the antibodies-negative group (n ¼ 106), respectively (P ¼ .47).
by solid line. (B) OS according to the type of anti-HLA antibodies. Group B had tenden
group A (47.5% [95% CI, 31.0% to 62.3%], n ¼ 39) or the antibodies-negative group (46.
Group A is represented by dotted line, group B by dashed line, and negative group bCBT. In particular, among patients with antibodies only
against HLA-A, -B, or -DRB1 (group A), the results were
comparable with those without antibodies. These observa-
tions strongly support that necessity to screen for DSA before
the selection of CB units, and indicated that CBT is an avail-
able option.
On the other hand, patients with antibodies including
HLA-C, -DP, -DQ, or -DRB3/4/5 (group B) showed a lower
incidence of engraftment compared with those only having
donor nonspeciﬁc anti-HLA-A, -B, -DRB1 antibodies, “true
non-DSA,” or those without antibodies, especially in HLA-
mismatched CBT. The ﬁndings suggest that unrecognized
DSA against for HLA-C, -DP, -DQ, or -DRB3/4/5 might
adversely affect engraftment after CBT. All previous studies
of anti-HLA antibodies performed in the CBT ﬁeld have
speciﬁcally looked at anti-HLA-A, -B, and -DRB1 antibodies in
the recipient [12-15], and the clinical signiﬁcance of anti-HLA
antibodies against HLA-C, -DP, -DQ, or -DRB3/4/5 has not
been investigated so far. In the largest study of anti-HLA
antibodies after CBT reported by Takanashi et al., patients
who had anti-HLA antibodies, except for donor-speciﬁc anti-
HLA-A, -B, -DRB1 antibodies, showed signiﬁcantly lower
neutrophil engraftment compared with those without anti-
HLA antibodies (73% versus 83%) [12]. One possible reason
for the lower engraftment rate in that study might be the
existence of unrecognized DSA against HLA-C, -DP, -DQ, or
-DRB3/4/5, as suggested in the present study. In unrelated
Allo-SCT, anti-DPB1 DSA has been recognized to be associ-
ated with increased risk for engraftment failure [25,26]. In
the setting of HLA-mismatched CBT, additional mismatch in
the HLA-C, -DP, -DQ, or -DRB3/4/5 antigens could likely be
present because of linkage disequilibrium, especially be-
tween the HLA-B and -C locus, or the -DRB1 and -DQ locus,
respectively [27,28]. In this study, therewere 12 patients who
had antibodies against HLA-DQ, and 7 were matched and 5
were mismatched for DRB1. Neutrophil recovery was
observed in all 7 HLA-DRB1ematched and 3 of 5 in the
mismatched group. The results further strengthen the asso-
ciation of DSA against HLA-DQ with engraftment failure.
Moreover, HLA-DP and -DQ antigens are also known to be
expressed on hematopoietic precursor cells [26,29-31]. Our
results, combined with previous ﬁndings, strongly suggest
the possibility of graft rejection associated with unrecog-
nized DSA against HLA-C, -DP, -DQ, -DRB3/4/5 antigens of an% CI, 30.5% to 54.7%) for the antibodies-positive group (n ¼ 69) and 46.2% (95%
Positive group represented by dashed line and the negative group represented
cy to decreased OS rate (35.1% [95% CI, 16.8% to 54.1%], n ¼ 30) compared with
2% [95% CI, 35.5% to 56.3%], n ¼ 106). (P ¼ .26; group B versus negative group).
y solid line.
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degree of HLA-mismatch in HVG direction had a signiﬁcantly
negative effect on engraftment. This result suggests that the
HLA-speciﬁc cellular immunity plays a critical role in
engraftment process, as previously reported [32,33]. How-
ever, in multivariate analysis for patients who received 2
antigen-mismatched CB, the presence of anti-HLA-C, -DP,
-DQ, -DRB3/4/5 antibodies was the negative factor for
neutrophil engraftment. Thus, in the setting of trans-
plantation using HLA-mismatched grafts, humoral immunity
could adversely affect engraftment.
Because this is a retrospective analysis, there is no infor-
mation available on HLA-DP, -DQ, or -DRB3/4/5 antigens of
CB units, negating direct assessment whether these antigens
were DSAs. We have done HLA-C typing retrospectively in 16
patients who had antieHLA-C antibodies. There were 2 pa-
tients who had DSA against HLA-C; 1 engrafted and the other
died early before engraftment. Among the remaining 14 who
did not have DSA against HLA-C, 2 developed engraftment
failure, 3 died early before engraftment, and 9 engrafted, and
with such a small sample size, we were not able to assess the
impact of DSA against HLA-C on engraftment. It remains to
be determined whether more mismatches in HLA-C, -DP,
-DQ, or -DRB3/4/5 antigens, or the combined effect of mis-
matches and DSA, have a negative effect on engraftment.
Furthermore, patients in group B showed a higher incidence
of NRM before engraftment, which could be associated with
the low engraftment rate. The high rate of early NRM
observed in group B became clear in the subgroup analysis
for patients who received 2 antigen-mismatched CB
(Supplementary Table S1). In the subgroup analysis for pa-
tients who survived for 28 days or longer after trans-
plantation and who received 2 antigen-mismatched CB
(n ¼ 110), group B (n ¼ 12) still tended to show a lower
engraftment rate compared with other groups (75% in group
B, 95.5% in group A, and 89.5% in negative group; group B
versus negative; P ¼ .30). Lower engraftment or delayed
neutrophil recovery observed in group B could have affected
this higher NRM. The presence of other factors that have an
impact on engraftment or earlymorality in group B cannot be
excluded, although background characteristics among group
B were almost comparable to the others (Supplementary
Table S1). In this study, the frequency of patients with anti-
HLA antibodies is higher compared with other previous se-
ries [11,12]. Our patient characteristics, including elderly or
heavily transfused patients, might have possibly affected the
result. The existence of a “natural antibody” is also one of the
factors to be considered [34,35]. The recent use of more
sensitive methods has resulted in the detection of low-level
antibodies not contributable to allogeneic antigens exposure.
When we re-evaluated our results based on cross-reactive
group [36,37], some antibodies seem to be classiﬁed as nat-
ural antibodies; however, we could not show their relevance
to the clinical outcomes.
In conclusion, our results demonstrate that the presence
of donor nonspeciﬁc anti-HLA-A, -B, -DRB1 antibodies had no
signiﬁcant inﬂuence on engraftment, NRM, and OS in HLA-
mismatched CBT. On the other hand, a high rate of engraft-
ment failure was seen in the presence of anti-HLA-C, -DP, -DQ,
or -DRB3/4/5 antibodies, suggesting unrecognized DSA against
HLA-C, -DP, -DQ, or -DRB3/4/5 antigens adversely affect
engraftment. Because this is a retrospective study including
a small and heterogeneous group of patients with various
characteristics, the results should be conﬁrmed by larger
scale studies involving information on HLA-C, -DP, -DQ, or-DRB3/4/5, which will establish the optimal strategies for
selecting CB units.
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